ライフサイエンスコーパス: ID50

1 ID50 and ID90 values for L-prolyl-L-m-[bis(chloroethyl)a

2 development of the following equation: log 1/ID50 = -1.39sigma+ - 0.28 B5(2,6) + 0.16 log P - 0.58I(2

3 ron-attracting phenols in L1210 cells, log 1/ID50 = 0.56 log P - 0.30 B5(2) + 2.79, suggests that hyd

4 Mice were vaginally challenged with 10 ID50 of HSV-2 either 3 or 7 days after disk placement; n

5 accines was determined by challenge with 100 ID50 of homotypic rotavirus.

6 (9.5) ID50 of LDV-C/ml contained about 10(5) ID50 of LDV-P/ml.

7 For example, various plasma pools of 10(9.5) ID50 of LDV-C/ml contained about 10(5) ID50 of LDV-P/ml.

8 ary to reduce cellular proliferation by 50% (ID50) was 222.1 microM.

9 esistance to CsA was greatly increased to an ID50 of > 1000 ng/ml.

10 This agent was highly effective, with an ID50 (50% inhibitory dose compared with control) of 0.00

11 mphoma/leukemia cells (EL4) in vitro with an ID50 in the range of 0.013-0.07 microg/ml (0.04-0.22 mic

12 Using the estimated LD50 and ID50 data, we dissected the kinetics of viral tissue dis

13 termined the number of PrP(Sc) molecules and ID50 units of prions that were retained in brain.

14 virus inhibitory dose neutralizing antibody (ID50) titer of 1000 correlated with 96% efficacy in prev

15 tivities determined in radioreceptor assays (ID50) and in vitro bioassays (ED50), it became evident t

16 e index (RI; ID50 resistant cells divided by ID50 sensitive cells) was lower than that of IDR and DOX

17 tes at concentrations lethal to tumor cells (ID50, 13.3 microM without and 11 microM with phytohemagg

18 nt for the TCID50 and other in vitro culture ID50 measures.

19 potently inhibited both Kv and KCa currents (ID50 = approximately 1 nM).

20 han the CCKA receptor antagonist devazepide (ID50 = 1760 ng).

21 ignificantly higher 50% inhibitory dilution (ID50) among DNA-primed positive responders (n = 53) vers

22 sters revealed that the 50% infectious dose (ID50 ) of spores was significantly higher (2-logs) in th

23 The 50% infectious dose (ID50) and lethal dose (LD50) of virus were estimated to

24 The 50% infectious dose (ID50) in hamsters was determined.

25 (TSE), resulting in one 50% infectious dose (ID50) remaining in every 5600 kg of final compost for la

26 The median infectious dose (ID50) was 5.1 x 105 GEC.

27 ion assay's output, the 50% infectious dose (ID50), is calculated using the Reed-Muench or Spearman-K

28 4)-fold increase in the 50% infectious dose (ID50).

29 es with a geometric mean 50% infective dose (ID50) between 100 and 800.

30 A 50% infectivity dose (ID50) of 2.60 x 10(6) CFU for fetuses was calculated by

31 serum samples increased 50% inhibitory dose (ID50) neutralizing antibody titers (up to 4.9-fold) in u

32 sary to colonize a host (50% infective dose [ID50]) was 5-fold higher for the arnT mutant.

33 ts and controls had median infectious doses (ID50) of 10(2) and 10(5) CFU, respectively.

34 etects as little as 10 50% infectious doses (ID50) of LDV.

35 tive to Dox than were cells in G1 phase (Dox ID50 = 0.50 +/- 0.16 microM in cells synchronized in S p

36 3 log g(-1) more bacteria than the estimated ID50 (2.83 CFU g(-1)), consistent with a soil-borne rese

37 The estimated ID50 to achieve 50%, 75%, and 95% protection was 91 (95%

38 anciclovir-resistant, which have ganciclovir ID50 values > or =30 microM and cross-resistance to cido

39 anciclovir-resistant, which have ganciclovir ID50 values > or =8 microM and <30 microM and sensitivit

40 , respectively, and two other inhibitors had ID50 values close to 1 microM.

41 7027, a "tetramer" of 2-hydroxy quinone, had ID50 values of 0.32 and 0.75 microM for HIV-1 protease i

42 endently inhibited mustard oil hyperalgesia (ID50 = 364 ng) at doses approximately 5-fold less than t

43 an abundance of one molecule per infectious (ID50) unit, we measured prions present after inoculation

44 A major loss of infectivity (ID50 > 10(3) cells) occurred with cells that lost the 24

45 ntration required to produce 50% inhibition (ID50) of polarization activated by N-acetyl-PGP.

46 ntly inhibited Kv (ID50 = 3 nM) but not KCa (ID50 = 5 microM) currents in T cells.

47 KTX potently inhibited Kv (ID50 = 3 nM) but not KCa (ID50 = 5 microM) currents in T

48 1210 cells were the same as the naive lines, ID50 0.5 microM.

49 lanine] against all leukemias and lymphomas, ID50 0.5-0.9 microM, and against human solid tumors, ID5

50 ited strongly by metyrapone and methoxsalen (ID50 < 1 microM, with DCBN at 30 microM), but only margi

51 akly inhibited by metyrapone or methoxsalen (ID50 > 50 microM).

52 tyl-PGP activation of polarization at 20 mM (ID50).

53 acy in the rabbit AV-shunt thrombosis model (ID50 = 0.6 mg/kg + 1 mg kg(-1) h(-1)).

54 os by stabilizing the 4 kDa A beta monomers (ID50 approximately equal to 3.4 microM).

55 Two months post-enrollment, nAb ID50 (ID80) titers declined 3.5 (2.8)-fold overall.

56 dovirus 50% neutralizing antibody titer (nAb ID50) measured two weeks post-dose two are assessed as c

57 In vaccine recipients with nAb ID50 titers of 50, 100, and 7230 international units (IU

58 ta- and ancestral-specific Spike IgG and nAb-ID50 at ~peak and over time as CoRs of severe COVID-19 a

59 Frequency of detectable nAb-ID50 titer was 98.3% (97.2, 99.0) for non-cases vs. 62.5

60 of 0.13 (95% CI: 0.03, 0.57) per 10-fold nAb-ID50 Delta increase.

61 e Vaccine Group [n = 115 (86 PWH)], Peak nAb-ID50 BA.4/5 correlates with reduced COVID-19 risk throug

62 Day 35 was 0.0338 (0.0043, 0.206) at the nAb-ID50 Delta 2.5th percentile (8.4 AU/ml), and 0.002 (0.00

63 tion BA.4/5 neutralizing antibody titer (nAb-ID50 BA.4/5) the strongest and only independent correlat

64 ry dilution neutralizing antibody titer (nAb-ID50) measured at 2 weeks post-dose 2 (~peak) were inver

65 severe cases (all inferred Delta), with nAb-ID50 Delta geometric mean 209.5 arbitrary units (AU)/mL

66 nees developed serum autologous tier 2 nAbs (ID50 titer, 1:28-1:8647) after two to three doses target

67 en peroxide production by human neutrophils (ID50 = 1-2 microg/mL).

68 We observed ID50 geometric mean titers >22 000 in both parasitemic a

69 fold reduction in receptor binding (based on ID50).

70 continuous exposure to 50 ng/ml paclitaxel (ID50) was mitotic arrest with an increase in the accumul

71 n our purified fractions at one molecule per ID50 unit is approximately 25 nucleotides in length.

72 000 protease-resistant PrP(Sc) molecules per ID50 unit after accounting for clearance of PrP(Sc) foll

73 odel, (R)-32 was observed to be very potent (ID50 = 91 ng/kg) and have a long duration of action (> 8

74 kage model, both showing excellent profiles (ID50 = 0.22 and 0.28 mg/kg, respectively).

75 emonstrated activity against HIV-1 protease (ID50 1.7 microM) but also exhibited promising antiviral

76 or without microtubule-associated proteins (ID50 was 0.1 microM and 1.2 microM, respectively) and mi

77 growth by 50% but its resistance index (RI; ID50 resistant cells divided by ID50 sensitive cells) wa

78 r bNAb epitopes and challenge viruses, serum ID50 had a highly significant effect on infection risk (

79 The ID50 differed among isolates: Iowa, 87 (SE, 19; 95% conf

80 The ID50 dosage of 13-MTD for these tumor cells ranged from

81 The ID50 for this response was 8-10 mg kg-1 daily dosing, an

82 The ID50 of CsA for the mixed lymphocyte response (MLR) was

83 The ID50 of the clone that possessed a full complement of ei

84 ntagonism of antinociception occurred at the ID50 dose for each antagonist at its homologous receptor

85 ine concentrations (1 microM) well below the ID50 had a 65% reduction in collagen production and a 57

86 acterized this model by determining both the ID50 and the LD50 of MERS-CoV in order to establish both

87 -2 release were highly sensitive to CsA, the ID50 being significantly less for HUVEC (6.5 ng/ml) than

88 We introduce a replacement for the ID50 that we call Specific INfection (SIN) along with a

89 ody developed in the surviving mice from the ID50/LD50 determinations, and all were fully immune to c

90 mitotic blocking activity and increased the ID50 40-fold.

91 A moderate decrease of the ID50 from 10(3) to 10(5) cells correlated with the loss

92 With ampicillin prophylaxis, the ID50 was 870 cfu for the beta-lactamase-negative isolate

93 mutant with either dbpA or dbpB reduced the ID50 from over 10(4) to roughly 10(3) organisms.

94 Similarly, the ID50 was greater for the beta-lactamase-negative isolate

95 We also show that the ID50 was higher in mice infected with R20291, a 'hypervi

96 en predicted serum 50% neutralization titer (ID50) against the challenge virus and infection outcome.

97 -0.9 microM, and against human solid tumors, ID50 0.4-2.1 microM.

98 of samples (P </= 0.0005), contrasting with ID50 neutralization titer increases in 2 of 70 double-ne

99 amples showed a significant correlation with ID50 neutralization titers when EP-II antibodies were re

100 The inhibition was dose dependent with ID50 values for the growth inhibition between 0.06 and 0

101 ells in early S phase with 1 microM Dox (2 x ID50) for 1 hr induced a marked cell arrest at G2/M phas